Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

To clarify the potential benefits of NACT before radical surgery(RS), we perform a phase III, randomised controlled trial to compare NACT plus RS with RS alone in patients with stages IB2 and IIA2 cervical cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Carboplatin; Cisplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Patients with newly histologically confirmed cervical carcinoma;

• Histopathology squamaous carcinoma, adenocarcinoma or adeno-squamous carcinoma;

• Original clinical stage must be IB2 or IIA2 （FIGO);

• Age between 18-65;

• Patients must give signed informed consent;

• P.S status: 0-1;

• Estimated survival time > 3 months;

Exclusion Criteria:

• The presence of uncontrolled life-threatening illness;

• Receiving other ways of anti-cancer therapy;

• Investigator consider the patients can't finish the whole study;

• With normal liver function test (ALT、AST>2.5×ULN);

• With normal renal function test (Creatinine>1.5×ULN);

• WBC<4,000/mm3 or PLT<100,000/mm;

• Accompany with other malignancy.